ASH 2021: A Focus on Leukemia & Lymphoma
Focus on Lymphoma Leukemia
Read More
ASH 2021
Ibrutinib Continues to Outperform Chemoimmunotherapy in Patients With Treatment-Naïve CLL
Ibrutinib was associated with prolonged progression-free survival (PFS) compared to the chemoimmunotherapy regimen bendamustine plus rituximab in older patients with treatment-naïve chronic lymphocytic leukemia (CLL). In...
Read MorePatients With Non-Hodgkin’s Lymphoma Subtypes Incur High Hospital Costs
According to published data, patients with mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL) experience frequent relapses over the course of...
Read MoreVenetoclax/Idelalisib Regimens Better Option After First-Line Ibrutinib for CLL/SLL
The establishment of ibrutinib as a preferred first-line treatment option makes it important to understand the treatment sequence following first-line ibrutinib and the patient characteristics of those treated with a second-line...
Read MoreDelayed Start of Therapy Feasible in Some Patients With MCL
Currently, the effect of the diagnosis-to-treatment interval (DTI) on survival in patients with mantle cell lymphoma (MCL) has not been extensively examined. Researchers aimed to determine the feasibility of active surveillance...
Read MoreAddition of Ibrutinib to Chemoimmunotherapy in CLL
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the only regimen other than allotransplantation shown in studies to result in a significant chance of functional cure in very long-term follow-up for...
Read More
Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL
With an updated median follow-up of 34.1 months, the 30-month progression-free survival (PFS) was 80.5% with ibrutinib plus venetoclax versus 35.8% for chlorambucil plus obinutuzumab in elderly or unfit patients with chronic...
Read MoreCAPTIVATE: Ibrutinib plus venetoclax show stunning efficacy in CLL
The first-line, chemotherapy-free regimen of ibrutinib plus venetoclax showed ongoing efficacy after 2 years of follow-up in patients with chronic lymphocytic leukemia (CLL). Patients with confirmed undetected Minimal Residual...
Read MoreReduced risk of Alzheimer’s disease in CHIP carriers
Clonal hematopoiesis of indeterminate potential (CHIP) was related to decreased risk of Alzheimer’s disease (AD) and AD neuropathological changes. Mutated hematopoietic stem cells were detected in the brains of CHIP carriers....
Read MoreUKALL 2003: therapy de-escalation safe in low-risk MRD patients with ALL
Therapy de-escalation in patients with acute lymphoblastic leukemia (ALL) and a low-risk minimal residual disease (MRD) profile was safe, 10-year follow-up results of the UKALL 2003 trial show. Patients with a high-risk MRD...
Read MoreHeavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen
A combination treatment of quizartinib plus venetoclax plus decitabine was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia (AML). Patients with RAS/MAPK and FLT3-F691L mutations...
Read MoreEncouraging results of novel triplet combination for AML
A regimen of cladribine plus low-dose cytarabine plus venetoclax alternated with 5-azacytidine plus venetoclax showed encouraging efficacy in patients with newly diagnosed acute myeloid leukemia (AML). Moreover, the displayed...
Read MorePromising frontline triplet regimen for TP53-mutated AML
A triplet combination of 5-azacitidine, venetoclax, and magrolimab displayed promising response rates in newly diagnosed older, unfit, or TP53-mutated patients with acute myeloid leukemia (AML). Moreover, the phase 1b/2 study...
Read MoreATLAS-INH: impressive results of fitusiran for hemophilia
Treatment with fitusiran prophylaxis led to a lower rate of bleeding events and an improved health-related quality of life in patients with hemophilia A or B with inhibitors. The observed safety profile of fitusiran in phase 3...
Read MoreJAK2V617F variant allele frequency prognostic of venous events in polycythaemia vera
JAK2V617F variant allele frequency (VAF) >50% is associated with an increased risk of venous thrombosis in patients with polycythaemia vera (PV). This independent predictor distinguished between patients who were classified...
Read MorePersistent disparities in ALL health outcomes
Significant disparities in health outcomes were observed across race, ethnicity, and socioeconomic status (SES) in patients with acute lymphoblastic leukemia (ALL). Differences in leukemia biology or disease prognosticators do...
Read MoreBenefits of eprenetapopt plus azacytidine for TP53-mutant MDS and oligoblastic AML
The combination therapy of eprenetapopt plus azacytidine showed favorable efficacy and safety in patients with TP53-mutant myelodysplastic syndrome (MDS) and oligoblastic acute myeloid leukemia (AML). Patients with biallelic...
Read MoreComparable effectiveness of CPX-351 and HMA plus venetoclax in older AML patients
Liposomal daunorubicin/cytarabine (CPX-351) therapy did not result in different overall survival (OS) outcomes or response rates than venetoclax plus HMA therapy in patients with acute myeloid leukemia (AML) between 60 and 75...
Read MorePromising results of tacrolimus plus dexamethasone in patients with immune thrombocytopenia
The combination regimen of low-dose tacrolimus plus high-dose dexamethasone provides benefits over high-dose dexamethasone monotherapy in patients with immune thrombocytopenia (ITP). Both the initial response rates and the...
Read More- 1
- 2